General Announcement::Takeda Submits New Drug Application for Novavax COVID-19 Vaccine Candidate in Japan

Issuer & Securities

Issuer/ Manager
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
16-Dec-2021 13:06:09
Status
New
Announcement Sub Title
Takeda Submits New Drug Application for Novavax COVID-19 Vaccine Candidate in Japan
Announcement Reference
SG211216OTHRRO4N
Submitted By (Co./ Ind. Name)
Izumi Masuyama
Designation
Manager of SEC Reporting
Description (Please provide a detailed description of the event in the box below)
Takeda Pharmaceutical Company Limited (Takeda) announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Japan for Novavax recombinant COVID-19 vaccine candidate, known as TAK-019 in Japan and NVX-CoV2373 outside Japan.

Attachments

Novavax COVID-19 Vaccine_121621.pdf
Total size =242K